EUVIMEDEUVIMED entdecken
Crossref

Good manufacturing practices production of human placental derived mesenchymal stem cells for therapeutic applications: focus on multiple sclerosis

Ameneh Shokati, Abdorreza Naser Moghadasi, Andisheh Ghashghaei, Mohammad Ali Sahraian, Bahram Chahardouli, Seyed Asadollah Mousavi, Jafar Ai, Mohsen Nikbakht

Molecular Biology Reports · 2024

DOI: 10.1007/s11033-024-09372-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Biology Reports, 2024. Verfasst von Ameneh Shokati und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Multiple Sclerosis, Mesenchymal Stem Cells. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Multiple Sclerosis Research Center to support this project, Research Institute for Oncology, Hematology& Cell Therapy Facility, Shariati Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Among neurological diseases, multiple sclerosis (MS) affects mostly young adults and can cause long-term disability. While most medications with approval from regulatory agencies are very effective in treating MS disease, they are unable to repair the tissue damage found in the central nervous system (CNS). Consequently, Cell-based therapy particularly using mesenchymal stem/stromal cells (MSCs), holds promise for neuroprotection and tissue repair in MS treatment. Furthermore, placenta-derived MSCs (PLMSCs) have shown the potential to treat MS due to their abundance, noninvasive isolation from discarded tissues, no ethical problems, anti-inflammatory, and reparative properties. Accordingly, good manufacturing practices (GMPs) plays a crucial part in clinical SCs manufacturing. The purpose of our article is to discuss GMP-grade PLMSC protocols for treating MS as well as other clinical applications. METHODS AND RESULTS: Placental tissue obtained of a healthy donor during the caesarean delivery and PLMSCs isolated by GMP standards. Flow cytometry was used to assess the expression of the CD markers CD34, CD105, CD90, and CD73 in the MSCs and the mesodermal differentiation ability was evaluated. Furthermore, Genetic evaluation of PLMSCs was done by G-banded karyotyping and revealed no chromosomal instability. In spite of the anatomical origin of the starting material, PLMSCs using this method of culture were maternal in origin. CONCLUSIONS: We hope that our protocol for clinical manufacturing of PLMSCs according to GMP standards will assist researchers in isolating MSCs from placental tissue for clinical and pre-clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisMesenchymal Stem CellsYoung AdultHumansFemalePregnancyPlacentaFlow CytometryCell- and Tissue-Based TherapyCells, CulturedCell DifferentiationCell Proliferation

Stichwörter der Autor:innen

Cell therapyClinical applicationGood manufacturing practiceMesenchymal stem cellsMultiple sclerosisPlacenta

Autor:innen und Institutionen

  • Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
  • Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences (TUMS), Tehran, Iran. abdorrezamoghadasi@gmail.com.
  • Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. jafar_ai@tums.ac.ir.
  • Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. m-nikbakht@sina.tums.ac.ir.

Förderung

  • Multiple Sclerosis Research Center to support this project
  • Research Institute for Oncology, Hematology& Cell Therapy Facility, Shariati Hospital

Zitieren

APA

Shokati, A., Naser Moghadasi, A., Ghashghaei, A., Sahraian, M. A., Chahardouli, B., Mousavi, S. A., Ai, J., & Nikbakht, M. (2024). Good manufacturing practices production of human placental derived mesenchymal stem cells for therapeutic applications: focus on multiple sclerosis. Molecular Biology Reports. https://doi.org/10.1007/s11033-024-09372-1

Vancouver

Shokati A, Naser Moghadasi A, Ghashghaei A, Sahraian MA, Chahardouli B, Mousavi SA, et al. Good manufacturing practices production of human placental derived mesenchymal stem cells for therapeutic applications: focus on multiple sclerosis. Molecular Biology Reports. 2024. doi:10.1007/s11033-024-09372-1

BibTeX
@article{Shokati2024,
  author = {Shokati, Ameneh and Naser Moghadasi, Abdorreza and Ghashghaei, Andisheh and Sahraian, Mohammad Ali and Chahardouli, Bahram and Mousavi, Seyed Asadollah and Ai, Jafar and Nikbakht, Mohsen},
  title = {Good manufacturing practices production of human placental derived mesenchymal stem cells for therapeutic applications: focus on multiple sclerosis},
  journal = {Molecular Biology Reports},
  year = {2024},
  doi = {10.1007/s11033-024-09372-1}
}
Kostenlos starten →